Trial Profile

Immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or peri-menopausal patients with early hormone receptor-positive breast cancer - the Promise study.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anastrozole (Primary) ; Goserelin (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
Indications Early breast cancer
Focus Therapeutic Use
Acronyms PROMISE

08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR357).
04 Jan 2012 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.
04 Jan 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com